Actemra™ Has A Major Impact On Improving Remission Rates In Rheumatoid Arthritis - 3 Studies From The Japanese Phase III Trial Programme

On the 13th November 2006, impressive results will be presented at ACR, the American College of Rheumatology, Washington D. C. These data highlight the outstanding symptom control with Actemra (tocilizumab) monotherapy for patients with rheumatoid arthritis (RA).


 
The studies showed impressive, consistent remission rates over time, culminating in more than half of patients receiving Actemra achieving remission at 12 months.


 
Actemra has the potential to become an exciting new therapeutic option for the treatment of RA, a disease with high unmet need where 60-80% of patients do not currently achieve adequate signs and symptoms control. 


 
A Phase III clinical development programme in RA is underway outside of Japan with more than 4,000 patients enrolled in 41 countries including countries in Europe and the USA.  Actemra has one of the largest clinical development programmes within Roche.


roche


View drug information on Actemra.